Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Net Cash Flow (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Net Cash Flow for 11 consecutive years, with $80.0 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow changed N/A to $80.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $203.3 million through Dec 2025, changed N/A year-over-year, with the annual reading at $178.6 million for FY2025, 674.63% up from the prior year.
  • Net Cash Flow for Q4 2025 was $80.0 million at Crescent Biopharma, down from $128.4 million in the prior quarter.
  • The five-year high for Net Cash Flow was $128.4 million in Q2 2025, with the low at -$16.9 million in Q3 2021.
  • Average Net Cash Flow over 5 years is $5.8 million, with a median of -$8.3 million recorded in 2022.
  • The sharpest move saw Net Cash Flow crashed 201.0% in 2022, then soared 224.7% in 2023.
  • Over 5 years, Net Cash Flow stood at -$11.7 million in 2021, then surged by 32.2% to -$7.9 million in 2022, then rose by 3.75% to -$7.6 million in 2023, then plummeted by 38.04% to -$10.5 million in 2024, then soared by 860.69% to $80.0 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at $80.0 million, $128.4 million, and -$5.1 million for Q4 2025, Q2 2025, and Q1 2025 respectively.